According to the World Cancer Research Fund International, approximately 968,784 new cases of gastric cancer were diagnosed in 2022 across the globe. Data suggests that gastric cancer ranks among the top three most common cancers in 19 countries and continues to be the leading cause of cancer mortality worldwide. The ongoing development of innovative and novel therapies shows a promising future for gastric cancer treatment.
The Gastric Cancer Pipeline Report by Expert Market Research gives comprehensive insights on the gastric cancer emerging drugs currently undergoing clinical trials and covers various aspects related to the details for each of these drugs under development. The gastric cancer report insights include the analysis of over 100 pipeline drugs and 50+ companies. Moreover, the analysis based on efficacy and safety measure outcomes published for the trials will be covered including their adverse effects in gastric cancer.
A detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing gastric cancer pipeline development activities are covered.
An abnormal cell growth in the stomach can lead to gastric cancer. Before the development of true cancer, pre-cancerous changes occur in the inner lining of the stomach. There are multiple types of gastric cancer which include adenocarcinoma of the stomach, Gastroesophageal Junction Adenocarcinoma (GEJ), gastrointestinal neuroendocrine tumors, and Gastrointestinal Stromal Tumors (GIST).
Gastric cancer treatment depends on the location of the cancer within the stomach and cancer stage. The treatment options include chemotherapy, targeted therapy and immunotherapy, radiation therapy and others. In 2021, the U.S. Food and Drug Administration amended its accelerated approval of the immu notherapy drug pembrolizumab (Keytruda) for treatment of advanced stomach cancer and gastroesophageal junction (GEJ) cancer.
Research studies shows that the drugs that target HER2 can be used to treat other cancers as well stomach cancer and GEJ cancer. Data suggests that 15% of patients with advanced stomach cancer have HER2-positive tumors. In November 2023, the U.S. Food and Drug Administration approved pembrolizumab combined with chemotherapy as an initial treatment for patients suffering from advanced stomach gastric that is HER2-negative.
The gastric cancer report covers the pathophysiology and epidemiology of gastric cancer, developing treatment, and the progress and future aspects of ongoing clinical trials for treatment in detail.
This section of the gastric cancer pipeline report covers the analysis of gastric cancer drugs based on various segmentations such as:
By Phase
EMR’s pipeline assessment report covers 50+ drug analysis based on phase.
By Route of Administration
EMR’s gastric cancer report assessment report covers 50+ drug analysis based on route of administration.
The gastric cancer pipeline landscape covers phase I, phase II, phase III, phase IV, and early phase drugs for Gastric cancer. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II trials cover major share of the total gastric cancer clinical trials conducted.
Nivolumab developed by Bristol-Myers Squibb is currently under phase II. The purpose of the study is to assess the safety and efficacy of Nivolumab in combination with Ipilimumab for the treatment of advanced gastric cancer.
The route of administration categories covered under gastric cancer clinical assessment include oral, parenteral and others. The report covers a comparative analysis of the route of administration for each drug in various phases of clinical trials of gastric cancer. According to EMR analysis, the parenteral route accounted for a major share of gastric cancer clinical trials.
The EMR report for the gastric cancer drug pipeline insight covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in gastric cancer clinical trials:
The EMR gastric cancer drug profiles cover the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for gastric cancer. Moreover, the section covers product description, trial ID, study type, drug class, mode of administration, and recruitment status among others.
Bemarit uzumab - Amgen
Amgen is conducting phase I clinical trials for bemarituzumab. The purpose of the study is to evaluate the safety and efficacy of bemarituzumab in combination with other anti-cancer therapies to treat multiple cancers including gastric cancer.
Everolimus - Novartis Pharmaceuticals
The purpose of the study is to evaluate the efficacy and safety of gastric cancer drug candidate RAD001 (Everolimus) monotherapy in patients suffering from advanced gastric cancer.
Trastuzumab - Hoffmann-La Roche
The study is under the observational phase and is sponsored by Hoffmann-La Roche. The primary purpose of the study is to evaluate Human HER-2 status in gastric cancer.
DS-8201a (DP1) - Daiichi Sankyo Co., L td.
Daiichi Sankyo Co., Ltd. Is conducting phase I trial to assess the safety of DS-8201a in participants suffering from advanced solid malignant tumors.
Global Gastric Ulcer Treatment Market
North America Gastric Cancer Drugs Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration |
|
| Drug Classes |
|
| Treatment Type |
|
| Leading Sponsors Covered |
|
| Geographies Covered |
|
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share